logo
Share SHARE
FONT-SIZE Plus   Neg

EResearchTechnology To Be Acquired By Affiliates Of Genstar Capital

eResearchTechnology, Inc. (ERT) said it has entered into a definitive agreement to be acquired by affiliates of Genstar Capital LLC for $8.00 per share in cash in a transaction valued at around $400 million. The transaction is expected to be completed during the third quarter.

The proposed transaction has been approved unanimously by eResearchTechnology's board of directors, following a recommendation by a special committee of independent directors, and suggests that the company's shareholders approve the transaction.

Dr. Jeffrey Litwin, CEO of ERT, added, "We are pleased to announce this transaction with Genstar, whose experienced team of healthcare executives can provide strategic oversight, as well as acquisition capital, to expand the company's service offering and market opportunities. They will help position ERT to better serve our clinical research clients by continuing to fund the innovative devices and services that have made us the premier provider of health outcomes research services."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Packaged food producer ConAgra Brands Inc. reported Thursday higher net profit in its fourth quarter with margin strength. Net sales, meanwhile, declined from last year on weak volume. Looking ahead, for fiscal 2018, the company projects higher adjusted earnings and lower to flat sales. The company also reiterated its three-year fiscal 2020 financial algorithm. Best Buy announced Wednesday its plans to introduce Amazon Alexa and Google Home experiences to its 700 locations across the U.S. starting next month as part of its strategy of pushing smart home technology. A nationwide rollout will be complete by the end of the year. The electronics retailer will expand space at selected stores to better showcase how Amazon's Echo and Google Home interact.. So far this year, 23 novel drugs have already received FDA approval. Now let's take a look at the biotech stocks waiting to hear from the FDA in July.
comments powered by Disqus
Follow RTT